)
Visual
test
Chemomab Therapeutics
Chemomab Therapeutics (CCMB) investor relations material
Chemomab Therapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary21 Nov, 2025
Executive summary
Advanced preparations for nebokitug Phase 3 trial in primary sclerosing cholangitis (PSC) with regulatory alignment from FDA and EMA for a single registration trial using a composite clinical endpoint.
Positive feedback and support from the PSC community and key opinion leaders for the Phase 3 trial design, with strong interest in trial participation.
Presented new clinical data at AASLD 2025 showing nebokitug's favorable safety and consistent improvements in key biomarkers in PSC patients treated up to 48 weeks.
Multiple partnering options for supporting the Phase 3 program are advancing, with a cash runway expected through the end of Q4 2026.
Financial highlights
Cash, cash equivalents, and short-term bank deposits totaled $10.2 million as of September 30, 2025, up from $9.5 million at June 30, 2025, but down from $14.2 million at December 31, 2024.
R&D expenses were $1 million in Q3 2025, down from $2.8 million in Q3 2024, reflecting the end of Phase 2 SPRING trial activities.
G&A expenses remained stable at $0.9 million for Q3 2025, similar to Q3 2024.
Net loss was $1.7 million for Q3 2025, compared to $3.5 million in Q3 2024.
492,409,320 ordinary shares (6,155,117 ADSs) were issued and outstanding as of September 30, 2025.
Outlook and guidance
Cash resources are expected to fund operations through the end of Q4 2026.
Plans to launch the nebokitug Phase 3 trial as soon as feasible, pending financial resources.
Phase 3 funding strategy details
Future R&D spend post-Phase 2 completion?
How does regulatory alignment impact trial timeline?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- YUM
Double-digit profit growth, digital expansion, and strategic actions defined the year. - 443060
Record 2025 revenue and profit, strong core growth, and robust 2026 outlook with high dividends. - GAIN
Record new investments and NAV growth highlight a strong quarter with robust distributions. - GAINRecord realized gains and income drove higher NAV and strong distributions in FY25.
- GAINNet investment income reached $9.1M, NAV per share was $12.99, and distributions stayed strong.
- EPAC
Directors, auditor, and executive pay were approved with strong shareholder participation. - ARCC
FY 2025 delivered $2.01 core EPS, $1.86/share net income, and a $29.5B portfolio. - GAINNAV per share rose to $13.53 on strong portfolio growth and stable adjusted NII.
- MATW
Net income $43.6M, sales $284.8M, debt reduced $174M, FY2026 EBITDA guidance $180M. - GM
Disciplined transformation, resilient cash flow, and software growth drive a strong outlook.
Next Chemomab Therapeutics earnings date
Q4 202527 Feb, 2026
Chemomab Therapeutics
Next Chemomab Therapeutics earnings date
Q4 202527 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Chemomab Therapeutics Ltd is an Israel-based clinical-stage biotechnology company focused on the development of therapies for fibrotic and inflammatory diseases. The company’s lead drug candidate is based on targeting CCL24, a chemokine involved in fibrosis and inflammation. Chemomab's pipeline includes treatments for conditions such as primary sclerosing cholangitis (PSC) and systemic sclerosis. The company conducts preclinical and clinical studies and collaborates with research institutions to advance its drug development efforts. Chemomab Therapeutics Ltd is headquartered in Tel Aviv, Israel, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage